Weight loss medications: What you need to know before you start

For many people, losing weight can feel frustrating and unpredictable.

Even with healthy habits, biological factors such as metabolism, hormones, insulin resistance, and genetics can make it harder to see results or maintain them over time.

A new era of weight loss support

Weight loss science has changed dramatically in just the past few years.
Medications like semaglutide (Wegovy® & Ozempic®) and tirzepatide (Zepbound® & Mounjaro®)¹ are leading a new wave of treatments that target the biological causes of weight gain.

Semaglutide and tirzepatide represent big medical advances in weight management. They help people lose weight more easily and sustain those results over time with healthy lifestyle changes.

These medications, known as GLP-1 receptor agonists, work by:

• Lowering appetite
• Slowing digestion
• Regulating blood sugar

Available through Noom Med, these treatments, when paired with improved lifestyle habits, support steady, sustainable weight loss.

Weight loss medications overview

Several different medications are now available to support healthy weight management.

Semaglutide (Wegovy® & Ozempic®)
Weekly injectable semaglutide medications have been shown to help people lose about 15%² of their starting weight on average at the highest doses when paired with healthy habits. 

• Wegovy® is FDA-approved for weight loss, while Ozempic® can be prescribed off-label. Wegovy® is available in a higher dose for those who need it. 

Tirzepatide (Zepbound® & Mounjaro®)
Also, once-weekly injectables, tirzepatide medications target GLP-1 and GIP receptors to help people lose an average of 15 to 21%³ of their starting weight, depending on the dose. 

• Zepbound® is FDA-approved for weight loss, while Mounjaro® can be prescribed off-label for weight loss. They are available in the same doses. 

Liraglutide (Saxenda®)
A daily injectable GLP-1 medication, Saxenda, is FDA-approved for weight loss. It isn’t as powerful as semaglutide or tirzepatide medications, but it supports gradual, consistent progress and helps people build sustainable long-term routines⁴.

All of these, and other clinically supported medications, are available through Noom Med if you qualify. You’ll be paired with licensed clinicians who help match you to the right treatment, prescribe it if appropriate, and help build a sustainable plan to support your goals.

Experience GLP-1 treatment with Noom

GLP-1 medications can be prescribed at different doses and through different care models depending on your needs, goals, and budget. Noom offers three options designed to make access easy and affordable.

1. Noom GLP-1^Rx Program
This is the option for people looking for full-dose GLP-1 medication with clinical guidance and proven behavioral support.

• Starts at $149 for the first month (medication included).
• Includes licensed clinician care, prescription medication, and digital behavior-change tools.
• Ideal for those who want comprehensive GLP-1 support and lasting results.

2. Noom Microdose GLP-1^Rx Program
A low-dose GLP-1 approach that still provides meaningful results with members achieving up to 11 pounds lost in 30 days⁵ and up to 17 pounds in 60 days⁶ at a more accessible price point than the Noom GLP-1Rx Program.

• Starts at $99 for the first month (medication included).
• Includes the same personalized care and support tools as the full-dose program.
• A great fit for those who want a gradual approach to weight management. Designed to minimize side effects.

3. Noom Telehealth for Branded Medications
For those who prefer to stay on or explore branded options like Wegovy®, Zepbound®, Ozempic®, or Mounjaro®, Noom offers telehealth access to licensed clinicians who can evaluate, prescribe, and coordinate care.

• $69 to get started, then $99/month for ongoing care (cost of medication is excluded).
• Noom helps manage the process and follow-up
• You use your own pharmacy and insurance coverage for the medication

All three paths include professional medical care, access to Noom’s digital tracking and support tools, and a focus on long-term weight management success.

Find which programs are best for you here

The safety of weight loss medications

GLP-1 weight-loss medications have been well-studied and are safe for most users when prescribed and monitored by a healthcare professional. However, it’s important to discuss side effects, possible risks, and long-term considerations with your clinician to ensure the right fit for you.

Noom’s clinicians specialize in weight-management care and can help you find the safest, most effective path for your goals.

How to get started

Starting your GLP-1 journey with Noom is simple and convenient.

1. Complete a short online assessment to see if you qualify.
2. Connect with an expert clinician.
3. Start losing weight with your customized plan
4. Ongoing care and medication

This easy, at-home process makes weight-loss care more accessible and personalized than ever.

Start your GLP-1 journey today.

A personal path to sustainable weight loss

Lasting change happens when the right tools, clinical support, and healthy habits come together.
With guidance from licensed clinicians and a science-based approach, Noom Med helps you take control of your health and move toward lasting results.

Note: Ozempic® and Mounjaro® are not FDA-approved to treat obesity or for weight loss.

1. ^{Novo Nordisk, Inc. is the only United States company with FDA-approved products containing semaglutide, identified under the trade names Rybelsus®, Ozempic®, and Wegovy®. Lilly USA LLC is the only United States company with FDA-approved products containing tirzepatide identified under the trade names Zepbound® and Mounjaro®} ↩︎
2. ^{Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight Âor Obesity. New England Journal of Medicine.} ↩︎
3. ^{Wilding JPH, Owen L, Lindgren P, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine.} ↩︎
4. ^{Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.} ↩︎
5. ^{Weight loss represents the top 25th percentile of self-reported data from 1,254 engaged Noom Med users with a BMI of 25 or greater and prescribed compounded GLP-1s that did not exceed the microdose dosage. Average weight loss for this group was 8 pounds in 30 days.} ↩︎
6. ^{Weight loss represents the top 25th percentile of self-reported data from 1,185 engaged Noom Med users with a BMI of 25 or greater and prescribed compounded GLP-1s that did not exceed the microdose dosage. Average weight loss for this group was 13 pounds in 60 days.} ↩︎